PET Radioactive Tracers Market by Product Type, End-Users, and Geography (North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa): Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032
Description
Persistence Market Research has recently released a comprehensive report on the worldwide market for PET radioactive tracers. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure.
Key Insights:
PET Radioactive Tracers Market Size (2025E): USD 1,069.8 Million
Projected Market Value (2032F): USD 1,706.7 Million
Global Market Growth Rate (CAGR 2025 to 2032): 6.9%
PET Radioactive Tracers Market - Report Scope:
PET radioactive tracers play a crucial role in the diagnosis and monitoring of various medical conditions, including cancer, cardiovascular diseases, and neurological disorders. These tracers, labeled with radioisotopes such as Fluorine-18, Carbon-11, and Gallium-68, emit positrons that are detected by PET scanners to produce high-resolution images of metabolic processes in the body. The PET radioactive tracers market caters to hospitals, diagnostic imaging centers, research laboratories, and academic institutions, offering a wide range of tracer types that support early disease detection, treatment planning, and drug development. Market growth is driven by increasing demand for precision diagnostics, rising healthcare investments, and technological advancements in radiopharmaceutical production.
Market Growth Drivers:
The global PET radioactive tracers market is propelled by several key factors, including growing awareness about PET imaging as a non-invasive and highly accurate diagnostic tool for detecting cancers, neurological conditions such as Alzheimer’s disease, and cardiac abnormalities. The increasing prevalence of chronic diseases and aging populations worldwide further drives the demand for effective diagnostic solutions. Technological innovations, such as the development of new tracer molecules and improved cyclotron production techniques, offer enhanced diagnostic performance and broader clinical applications, fostering market growth. Moreover, the rising adoption of hybrid imaging technologies, such as PET/CT and PET/MRI, and the expanding use of PET tracers in personalized medicine and targeted therapies create new avenues for market players to reach wider patient populations.
Market Restraints:
Despite promising growth prospects, the PET radioactive tracers market faces challenges related to regulatory compliance, production logistics, and infrastructure limitations. The manufacturing and distribution of PET tracers require highly specialized facilities, including cyclotrons and radiopharmacies, which involve significant capital investment and technical expertise. Additionally, the short half-life of many isotopes necessitates rapid production and local delivery, limiting the geographic reach of tracer supply. Stringent regulations governing the approval, handling, and transportation of radioactive materials impose compliance burdens on manufacturers and healthcare providers, affecting market accessibility and operational costs. Furthermore, the high cost of PET imaging procedures and limited reimbursement coverage in certain regions hinder widespread adoption.
Market Opportunities:
The PET radioactive tracers market presents significant growth opportunities driven by technological innovations, expanding clinical indications, and growing investment in nuclear medicine. The development of novel tracers targeting specific biomarkers in oncology, neurology, and cardiology enhances diagnostic precision and supports personalized treatment strategies. The integration of digital health technologies, such as AI-powered image analysis and remote diagnostics, improves workflow efficiency and patient outcomes. Furthermore, the increasing availability of compact and cost-effective cyclotron systems, especially in emerging economies, facilitates local production and distribution of tracers. Strategic collaborations between pharmaceutical companies, research institutions, and healthcare providers, along with favorable regulatory reforms, are essential to capitalize on emerging opportunities and sustain market leadership in the evolving PET imaging landscape.
Key Questions Answered in the Report:
What are the primary factors driving the growth of the PET radioactive tracers market globally?
Which tracer types and applications are driving adoption across different healthcare settings?
How are technological advancements reshaping the competitive landscape of the PET radioactive tracers market?
Who are the key players contributing to the PET radioactive tracers market, and what strategies are they employing to maintain market relevance?
What are the emerging trends and future prospects in the global PET radioactive tracers market?
Competitive Intelligence and Business Strategy:
These companies invest in R\&D to develop advanced tracer compounds, automated synthesis systems, and radiopharmaceutical platforms, catering to a broad spectrum of clinical and research needs. Collaborations with academic research institutions, pharmaceutical developers, and diagnostic service providers enable market access and promote tracer adoption. Moreover, emphasis on supply chain optimization, regulatory expertise, and regional manufacturing facilities enhances tracer availability and supports market expansion in high-demand and underserved regions.
Key Companies Profiled:
Eli Lilly and Company
Blue Earth Diagnostics
Lantheus
Siemens Healthcare Private Limited
GE Healthcare
Advanced Accelerator Applications (Novartis)
University of Lowa HealthCare
Telix Pharmaceuticals Limited
Jubilant Radiopharma
TRASIS
RadioMedix Inc.
IBA Radiopharma Solutions
Piramal Imaging (Life Molecular Imaging)
Cardinal Health
DuchemBio, Co. Ltd.
PET Radioactive Tracers Market Research Segmentation:
Product:
F-18
N-13
Cu-64
Application:
Neurological Disorders
Others
End User:
Hospitals
Speciality Diagnostic Centers
Cancer Research Centers
Academic & Research Institutes
Region:
North America
Latin America
East Asia
South Asia & Pacific
Western Europe
Eastern Europe
Central Asia
Russia & Belarus
Balkan & Baltic Countries
Middle East & Africa
Key Insights:
PET Radioactive Tracers Market Size (2025E): USD 1,069.8 Million
Projected Market Value (2032F): USD 1,706.7 Million
Global Market Growth Rate (CAGR 2025 to 2032): 6.9%
PET Radioactive Tracers Market - Report Scope:
PET radioactive tracers play a crucial role in the diagnosis and monitoring of various medical conditions, including cancer, cardiovascular diseases, and neurological disorders. These tracers, labeled with radioisotopes such as Fluorine-18, Carbon-11, and Gallium-68, emit positrons that are detected by PET scanners to produce high-resolution images of metabolic processes in the body. The PET radioactive tracers market caters to hospitals, diagnostic imaging centers, research laboratories, and academic institutions, offering a wide range of tracer types that support early disease detection, treatment planning, and drug development. Market growth is driven by increasing demand for precision diagnostics, rising healthcare investments, and technological advancements in radiopharmaceutical production.
Market Growth Drivers:
The global PET radioactive tracers market is propelled by several key factors, including growing awareness about PET imaging as a non-invasive and highly accurate diagnostic tool for detecting cancers, neurological conditions such as Alzheimer’s disease, and cardiac abnormalities. The increasing prevalence of chronic diseases and aging populations worldwide further drives the demand for effective diagnostic solutions. Technological innovations, such as the development of new tracer molecules and improved cyclotron production techniques, offer enhanced diagnostic performance and broader clinical applications, fostering market growth. Moreover, the rising adoption of hybrid imaging technologies, such as PET/CT and PET/MRI, and the expanding use of PET tracers in personalized medicine and targeted therapies create new avenues for market players to reach wider patient populations.
Market Restraints:
Despite promising growth prospects, the PET radioactive tracers market faces challenges related to regulatory compliance, production logistics, and infrastructure limitations. The manufacturing and distribution of PET tracers require highly specialized facilities, including cyclotrons and radiopharmacies, which involve significant capital investment and technical expertise. Additionally, the short half-life of many isotopes necessitates rapid production and local delivery, limiting the geographic reach of tracer supply. Stringent regulations governing the approval, handling, and transportation of radioactive materials impose compliance burdens on manufacturers and healthcare providers, affecting market accessibility and operational costs. Furthermore, the high cost of PET imaging procedures and limited reimbursement coverage in certain regions hinder widespread adoption.
Market Opportunities:
The PET radioactive tracers market presents significant growth opportunities driven by technological innovations, expanding clinical indications, and growing investment in nuclear medicine. The development of novel tracers targeting specific biomarkers in oncology, neurology, and cardiology enhances diagnostic precision and supports personalized treatment strategies. The integration of digital health technologies, such as AI-powered image analysis and remote diagnostics, improves workflow efficiency and patient outcomes. Furthermore, the increasing availability of compact and cost-effective cyclotron systems, especially in emerging economies, facilitates local production and distribution of tracers. Strategic collaborations between pharmaceutical companies, research institutions, and healthcare providers, along with favorable regulatory reforms, are essential to capitalize on emerging opportunities and sustain market leadership in the evolving PET imaging landscape.
Key Questions Answered in the Report:
What are the primary factors driving the growth of the PET radioactive tracers market globally?
Which tracer types and applications are driving adoption across different healthcare settings?
How are technological advancements reshaping the competitive landscape of the PET radioactive tracers market?
Who are the key players contributing to the PET radioactive tracers market, and what strategies are they employing to maintain market relevance?
What are the emerging trends and future prospects in the global PET radioactive tracers market?
Competitive Intelligence and Business Strategy:
These companies invest in R\&D to develop advanced tracer compounds, automated synthesis systems, and radiopharmaceutical platforms, catering to a broad spectrum of clinical and research needs. Collaborations with academic research institutions, pharmaceutical developers, and diagnostic service providers enable market access and promote tracer adoption. Moreover, emphasis on supply chain optimization, regulatory expertise, and regional manufacturing facilities enhances tracer availability and supports market expansion in high-demand and underserved regions.
Key Companies Profiled:
Eli Lilly and Company
Blue Earth Diagnostics
Lantheus
Siemens Healthcare Private Limited
GE Healthcare
Advanced Accelerator Applications (Novartis)
University of Lowa HealthCare
Telix Pharmaceuticals Limited
Jubilant Radiopharma
TRASIS
RadioMedix Inc.
IBA Radiopharma Solutions
Piramal Imaging (Life Molecular Imaging)
Cardinal Health
DuchemBio, Co. Ltd.
PET Radioactive Tracers Market Research Segmentation:
Product:
F-18
- Florbetapir
- Florbetaben
- Flutemetamol
- Fludeoxyglucose
- Sodium Fluoride
- Others
- Choline
- Methionine
- Others
- DOTA-TOC
- DOTATATE
- DOTANOC
- Others
N-13
Cu-64
Application:
Neurological Disorders
- Alzheimer’s Disease
- Dementia
- Others
- Solid Tumors
- Hematology Tumors
- Myocardial Infarction
- Others
Others
End User:
Hospitals
Speciality Diagnostic Centers
Cancer Research Centers
Academic & Research Institutes
Region:
North America
Latin America
East Asia
South Asia & Pacific
Western Europe
Eastern Europe
Central Asia
Russia & Belarus
Balkan & Baltic Countries
Middle East & Africa
Table of Contents
350 Pages
- 1. Executive Summary
- 1.1. Global Market Outlook
- 1.2. Demand Side Trends
- 1.3. Supply Side Trends
- 1.4. Analysis and Recommendations
- 2. Market Overview
- 2.1. Market Coverage / Taxonomy
- 2.2. Market Definition / Scope / Limitations
- 2.3. Inclusion and Exclusions
- 3. Key Market Trends
- 3.1. Key Trends Impacting the Market
- 3.2. Innovation / Development Trends
- 4. Key Success Factors
- 4.1. PET Scanner Installed Base Scenario
- 4.2. Number of PET Scans, By Country
- 4.3. Disease Epidemiology
- 4.4. Product Adoption/Usage Analysis
- 4.5. Regulatory Approval Pathway
- 4.6. Reimbursement Scenario
- 4.7. Technology Advancements
- 4.8. Good Manufacturing Practice (cGMP)
- 4.9. Value Chain Analysis
- 4.10. Quality Standards/Accreditations
- 4.11. PESTEL Analysis
- 4.12. Porter’s Analysis
- 5. Market Background
- 5.1. Macro-Economic Factors
- 5.1.1. Global GDP Outlook
- 5.1.2. Global Healthcare Expenditure Outlook
- 5.1.3. Oncology Spending
- 5.2. Forecast Factors - Relevance & Impact
- 5.2.1. Development of Novel Products
- 5.2.2. Regulatory Imposition
- 5.2.3. Increasing Spending on Targeted Therapies
- 5.2.4. Increasing Prevalence of Cancer
- 5.2.5. Strategic Mergers and Acquisitions among Local Players
- 5.2.6. Rising Awareness towards Development of Disease
- 5.3. Market Dynamics
- 5.3.1. Drivers
- 5.3.2. Restraints
- 5.3.3. Opportunity Analysis
- 6. COVID-19 Crisis Analysis
- 6.1. 2021 Market Scenario
- 6.2. COVID-19 and Impact Analysis
- 6.2.1. By Product
- 6.2.2. By Application
- 6.2.3. By End User
- 6.2.4. By Region
- 7. Global Market Demand (in Value or Size in US$ Mn) Analysis 2019–2024 and Forecast, 2025–2032
- 7.1. Historical Market Value (US$ Mn) Analysis, 2019–2024
- 7.2. Current and Future Market Value (US$ Mn) Projections, 2025–2032
- 7.2.1. Y-o-Y Growth Trend Analysis
- 7.2.2. Absolute $ Opportunity Analysis
- 8. Global Market Analysis 2019–2024 and Forecast 2025–2032, By Product
- 8.1. Introduction / Key Findings
- 8.2. Historical Market Size (US$ Mn) Analysis By Product, 2019–2024
- 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Product, 2025–2032
- 8.3.1. F-18
- 8.3.1.1. Florbetapir
- 8.3.1.2. Florbetaben
- 8.3.1.3. Flutemetamol
- 8.3.1.4. Fludeoxyglucose
- 8.3.1.5. Sodium Fluoride
- 8.3.1.6. Others
- 8.3.2. C-11
- 8.3.2.1. Choline
- 8.3.2.2. Methionine
- 8.3.2.3. Others
- 8.3.3. Ga-68
- 8.3.3.1. DOTA-TOC
- 8.3.3.2. DOTATATE
- 8.3.3.3. DOTANOC
- 8.3.3.4. Others
- 8.3.4. O-15
- 8.3.5. N-13
- 8.3.6. Cu-64
- 8.4. Market Attractiveness Analysis By End User
- 9. Global Market Analysis 2019–2024 and Forecast 2025–2032, By Application
- 9.1. Introduction / Key Findings
- 9.2. Historical Market Size (US$ Mn) Analysis By Application, 2019–2024
- 9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Application, 2025–2032
- 9.3.1. Neurological Disorders
- 9.3.1.1. Alzheimer’s Disease
- 9.3.1.2. Dementia
- 9.3.1.3. Others
- 9.3.2. Cancer Diagnosis & Prognosis
- 9.3.2.1. Solid Tumor
- 9.3.2.2. Hematology Tumor
- 9.3.3. Cardiac Dysfunctions
- 9.3.3.1. Myocardial Infarction
- 9.3.3.2. Others
- 9.3.4. Infectious disease Diagnosis
- 9.3.5. Others
- 9.4. Market Attractiveness Analysis By End User
- 10. Global Market Analysis 2019–2024 and Forecast 2025–2032, By End User
- 10.1. Introduction / Key Findings
- 10.2. Historical Market Size (US$ Mn) Analysis By End User, 2019–2024
- 10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By End User, 2025–2032
- 10.3.1. Hospitals
- 10.3.2. Speciality Diagnostic Centers
- 10.3.3. Cancer Research Centers
- 10.3.4. Academic & Research Institutes
- 10.4. Market Attractiveness Analysis By End User
- 11. Global Market Analysis 2019–2024 and Forecast 2025–2032, By Region
- 11.1. Introduction
- 11.2. Historical Market Size (US$ Mn) Analysis By Region, 2019–2024
- 11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Region, 2025–2032
- 11.3.1. North America
- 11.3.2. Latin America
- 11.3.3. East Asia
- 11.3.4. South Asia & Pacific
- 11.3.5. Western Europe
- 11.3.6. Eastern Europe
- 11.3.7. Central Asia
- 11.3.8. Russia & Belarus
- 11.3.9. Balkan & Baltic Countries
- 11.3.10. Middle East & Africa
- 11.4. Market Attractiveness Analysis By Region
- 12. North America Market Analysis 2019–2024 and Forecast 2025–2032
- 12.1. Introduction
- 12.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019–2024
- 12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2025–2032
- 12.3.1. By Country
- 12.3.1.1. U.S.
- 12.3.1.2. Canada
- 12.3.2. By Product
- 12.3.3. By Application
- 12.3.4. By End User
- 12.4. Market Attractiveness Analysis
- 12.4.1. By Country
- 12.4.2. By Product
- 12.4.3. By Application
- 12.4.4. By End User
- 12.5. Key Market Trends
- 12.6. Drivers and Restraints - Impact Analysis
- 12.7. Key Players - Intensity Mapping
- 12.8. Country Level Analysis & Forecast
- 12.8.1. U.S. Market
- 12.8.1.1. Introduction
- 12.8.1.2. Market Analysis and Forecast by Market Taxonomy
- 12.8.1.2.1. By Product
- 12.8.1.2.2. By Application
- 12.8.1.2.3. By End User
- 12.8.2. Canada Market
- 12.8.2.1. Introduction
- 12.8.2.2. Market Analysis and Forecast by Market Taxonomy
- 12.8.2.2.1. By Product
- 12.8.2.2.2. By Application
- 12.8.2.2.3. By End User
- 13. Latin America Market Analysis 2019–2024 and Forecast 2025–2032
- 13.1. Introduction
- 13.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019–2024
- 13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2025–2032
- 13.3.1. By Country
- 13.3.1.1. Brazil
- 13.3.1.2. Argentina
- 13.3.1.3. Mexico
- 13.3.1.4. Rest of Latin America
- 13.3.2. By Product
- 13.3.3. By Application
- 13.3.4. By End User
- 13.4. Market Attractiveness Analysis
- 13.4.1. By Country
- 13.4.2. By Product
- 13.4.3. By Application
- 13.4.4. By End User
- 13.5. Key Market Trends
- 13.6. Drivers and Restraints - Impact Analysis
- 13.7. Key Players - Intensity Mapping
- 13.8. Country Level Analysis & Forecast
- 13.8.1. Brazil Market
- 13.8.1.1. Introduction
- 13.8.1.2. Market Analysis and Forecast by Market Taxonomy
- 13.8.1.2.1. By Product
- 13.8.1.2.2. By Application
- 13.8.1.2.3. By End User
- 13.8.2. Argentina Market
- 13.8.2.1. Introduction
- 13.8.2.2. Market Analysis and Forecast by Market Taxonomy
- 13.8.2.2.1. By Product
- 13.8.2.2.2. By Application
- 13.8.2.2.3. By End User
- 13.8.3. Mexico Market
- 13.8.3.1. Introduction
- 13.8.3.2. Market Analysis and Forecast by Market Taxonomy
- 13.8.3.2.1. By Product
- 13.8.3.2.2. By Application
- 13.8.3.2.3. By End User
- 14. East Asia Market Analysis 2019–2024 and Forecast 2025–2032
- 14.1. Introduction
- 14.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019–2024
- 14.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2025–2032
- 14.3.1. By Country
- 14.3.1.1. China
- 14.3.1.2. Japan
- 14.3.1.3. South Korea
- 14.3.2. By Product
- 14.3.3. By Application
- 14.3.4. By End User
- 14.4. Market Attractiveness Analysis
- 14.4.1. By Country
- 14.4.2. By Product
- 14.4.3. By Application
- 14.4.4. By End User
- 14.5. Key Market Trends
- 14.6. Drivers and Restraints - Impact Analysis
- 14.7. Key Players - Intensity Mapping
- 14.8. Country Level Analysis & Forecast
- 14.8.1. China Market
- 14.8.1.1. Introduction
- 14.8.1.2. Market Analysis and Forecast by Market Taxonomy
- 14.8.1.2.1. By Product
- 14.8.1.2.2. By Application
- 14.8.1.2.3. By End User
- 14.8.2. Japan Market
- 14.8.2.1. Introduction
- 14.8.2.2. Market Analysis and Forecast by Market Taxonomy
- 14.8.2.2.1. By Product
- 14.8.2.2.2. By Application
- 14.8.2.2.3. By End User
- 14.8.3. South Korea Market
- 14.8.3.1. Introduction
- 14.8.3.2. Market Analysis and Forecast by Market Taxonomy
- 14.8.3.2.1. By Product
- 14.8.3.2.2. By Application
- 14.8.3.2.3. By End User
- 15. South Asia & Pacific Market Analysis 2019–2024 and Forecast 2025–2032
- 15.1. Introduction
- 15.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019–2024
- 15.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2025–2032
- 15.3.1. By Country
- 15.3.1.1. India
- 15.3.1.2. Indonesia
- 15.3.1.3. Thailand
- 15.3.1.4. Philippines
- 15.3.1.5. Malaysia
- 15.3.1.6. Vietnam
- 15.3.1.7. Rest of ASEAN
- 15.3.1.8. Australia & New Zealand
- 15.3.2. By Product
- 15.3.3. By Application
- 15.3.4. By End User
- 15.4. Market Attractiveness Analysis
- 15.4.1. By Country
- 15.4.2. By Product
- 15.4.3. By Application
- 15.4.4. By End User
- 15.5. Key Market Trends
- 15.6. Drivers and Restraints - Impact Analysis
- 15.7. Key Players - Intensity Mapping
- 15.8. Country Level Analysis & Forecast
- 15.8.1. India Market
- 15.8.1.1. Introduction
- 15.8.1.2. Market Analysis and Forecast by Market Taxonomy
- 15.8.1.2.1. By Product
- 15.8.1.2.2. By Application
- 15.8.1.2.3. By End User
- 15.8.2. Indonesia Market
- 15.8.2.1. Introduction
- 15.8.2.2. Market Analysis and Forecast by Market Taxonomy
- 15.8.2.2.1. By Product
- 15.8.2.2.2. By Application
- 15.8.2.2.3. By End User
- 15.8.3. Thailand Market
- 15.8.3.1. Introduction
- 15.8.3.2. Market Analysis and Forecast by Market Taxonomy
- 15.8.3.2.1. By Product
- 15.8.3.2.2. By Application
- 15.8.3.2.3. By End User
- 15.8.4. Philippines Market
- 15.8.4.1. Introduction
- 15.8.4.2. Market Analysis and Forecast by Market Taxonomy
- 15.8.4.2.1. By Product
- 15.8.4.2.2. By Application
- 15.8.4.2.3. By End User
- 15.8.5. Malaysia Market
- 15.8.5.1. Introduction
- 15.8.5.2. Market Analysis and Forecast by Market Taxonomy
- 15.8.5.2.1. By Product
- 15.8.5.2.2. By Application
- 15.8.5.2.3. By End User
- 15.8.6. Vietnam Market
- 15.8.6.1. Introduction
- 15.8.6.2. Market Analysis and Forecast by Market Taxonomy
- 15.8.6.2.1. By Product
- 15.8.6.2.2. By Application
- 15.8.6.2.3. By End User
- 15.8.7. Australia & New Zealand Market
- 15.8.7.1. Introduction
- 15.8.7.2. Market Analysis and Forecast by Market Taxonomy
- 15.8.7.2.1. By Product
- 15.8.7.2.2. By Application
- 15.8.7.2.3. By End User
- 16. Western Europe Market Analysis 2019–2024 and Forecast 2025–2032
- 16.1. Introduction
- 16.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019–2024
- 16.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2025–2032
- 16.3.1. By Country
- 16.3.1.1. Germany
- 16.3.1.2. France
- 16.3.1.3. Spain
- 16.3.1.4. Italy
- 16.3.1.5. BENELUX
- 16.3.1.6. Nordic Countries
- 16.3.1.7. United Kingdom
- 16.3.2. By Product
- 16.3.3. By Application
- 16.3.4. By End User
- 16.4. Market Attractiveness Analysis
- 16.4.1. By Country
- 16.4.2. By Product
- 16.4.3. By Application
- 16.4.4. By End User
- 16.5. Key Market Trends
- 16.6. Drivers and Restraints - Impact Analysis
- 16.7. Key Players - Intensity Mapping
- 16.8. Country Level Analysis & Forecast
- 16.8.1. Germany Market
- 16.8.1.1. Introduction
- 16.8.1.2. Market Analysis and Forecast by Market Taxonomy
- 16.8.1.2.1. By Product
- 16.8.1.2.2. By Application
- 16.8.1.2.3. By End User
- 16.8.2. France Market
- 16.8.2.1. Introduction
- 16.8.2.2. Market Analysis and Forecast by Market Taxonomy
- 16.8.2.2.1. By Product
- 16.8.2.2.2. By Application
- 16.8.2.2.3. By End User
- 16.8.3. Spain Market
- 16.8.3.1. Introduction
- 16.8.3.2. Market Analysis and Forecast by Market Taxonomy
- 16.8.3.2.1. By Product
- 16.8.3.2.2. By Application
- 16.8.3.2.3. By End User
- 16.8.4. Italy Market
- 16.8.4.1. Introduction
- 16.8.4.2. Market Analysis and Forecast by Market Taxonomy
- 16.8.4.2.1. By Product
- 16.8.4.2.2. By Application
- 16.8.4.2.3. By End User
- 16.8.5. BENULUX Market
- 16.8.5.1. Introduction
- 16.8.5.2. Market Analysis and Forecast by Market Taxonomy
- 16.8.5.2.1. By Product
- 16.8.5.2.2. By Application
- 16.8.5.2.3. By End User
- 16.8.6. Nordic Countries Market
- 16.8.6.1. Introduction
- 16.8.6.2. Market Analysis and Forecast by Market Taxonomy
- 16.8.6.2.1. By Product
- 16.8.6.2.2. By Application
- 16.8.6.2.3. By End User
- 16.8.7. U.K. Market
- 16.8.7.1. Introduction
- 16.8.7.2. Market Analysis and Forecast by Market Taxonomy
- 16.8.7.2.1. By Product
- 16.8.7.2.2. By Application
- 16.8.7.2.3. By End User
- 17. Eastern Europe Market Analysis 2019–2024 and Forecast 2025–2032
- 17.1. Introduction
- 17.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019–2024
- 17.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2025–2032
- 17.3.1. By Country
- 17.3.1.1. Poland
- 17.3.1.2. Hungary
- 17.3.1.3. Romania
- 17.3.1.4. Czech Republic
- 17.3.1.5. Rest of Eastern Europe
- 17.3.2. By Product
- 17.3.3. By Application
- 17.3.4. By End User
- 17.4. Market Attractiveness Analysis
- 17.4.1. By Country
- 17.4.2. By Product
- 17.4.3. By Application
- 17.4.4. By End User
- 17.5. Key Market Trends
- 17.6. Drivers and Restraints - Impact Analysis
- 17.7. Key Players - Intensity Mapping
- 17.8. Country Level Analysis & Forecast
- 17.8.1. Poland Market
- 17.8.1.1. Introduction
- 17.8.1.2. Market Analysis and Forecast by Market Taxonomy
- 17.8.1.2.1. By Product
- 17.8.1.2.2. By Application
- 17.8.1.2.3. By End User
- 17.8.2. Hungary Market
- 17.8.2.1. Introduction
- 17.8.2.2. Market Analysis and Forecast by Market Taxonomy
- 17.8.2.2.1. By Product
- 17.8.2.2.2. By Application
- 17.8.2.2.3. By End User
- 17.8.3. Romania Market
- 17.8.3.1. Introduction
- 17.8.3.2. Market Analysis and Forecast by Market Taxonomy
- 17.8.3.2.1. By Product
- 17.8.3.2.2. By Application
- 17.8.3.2.3. By End User
- 17.8.4. Czech Republic Market
- 17.8.4.1. Introduction
- 17.8.4.2. Market Analysis and Forecast by Market Taxonomy
- 17.8.4.2.1. By Product
- 17.8.4.2.2. By Application
- 17.8.4.2.3. By End User
- 18. Central Asia Market Analysis 2019–2024 and Forecast 2025–2032
- 18.1. Introduction
- 18.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019–2024
- 18.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2025–2032
- 18.3.1. By Product
- 18.3.2. By Application
- 18.3.3. By End User
- 18.4. Market Attractiveness Analysis
- 18.4.1. By Product
- 18.4.2. By Application
- 18.4.3. By End User
- 18.5. Key Market Trends
- 18.6. Drivers and Restraints - Impact Analysis
- 18.7. Key Players - Intensity Mapping
- 19. Russia & Belarus Market Analysis 2019–2024 and Forecast 2025–2032
- 19.1. Introduction
- 19.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019–2024
- 19.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2025–2032
- 19.3.1. By Product
- 19.3.2. By Application
- 19.3.3. By End User
- 19.4. Market Attractiveness Analysis
- 19.4.1. By Product
- 19.4.2. By Application
- 19.4.3. By End User
- 19.5. Key Market Trends
- 19.6. Drivers and Restraints - Impact Analysis
- 19.7. Key Players - Intensity Mapping
- 20. Balkan & Baltic Countries Asia Market Analysis 2019–2024 and Forecast 2025–2032
- 20.1. Introduction
- 20.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019–2024
- 20.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2025–2032
- 20.3.1. By Product
- 20.3.2. By Application
- 20.3.3. By End User
- 20.4. Market Attractiveness Analysis
- 20.4.1. By Product
- 20.4.2. By Application
- 20.4.3. By End User
- 20.5. Key Market Trends
- 20.6. Drivers and Restraints - Impact Analysis
- 20.7. Key Players - Intensity Mapping
- 21. Middle East and Africa (MEA) Market Analysis 2019–2024 and Forecast 2025–2032
- 21.1. Introduction
- 21.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019–2024
- 21.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2025–2032
- 21.3.1. By Country
- 21.3.1.1. GCC Countries
- 21.3.1.2. Kingdom of Saudi Arabia
- 21.3.1.3. Türkiye
- 21.3.1.4. Northern Africa
- 21.3.1.5. South Africa
- 21.3.1.6. Israel
- 21.3.2. By Product
- 21.3.3. By Application
- 21.3.4. By End User
- 21.4. Market Attractiveness Analysis
- 21.4.1. By Country
- 21.4.2. By Product
- 21.4.3. By Application
- 21.4.4. By End User
- 21.5. Key Market Trends
- 21.6. Drivers and Restraints - Impact Analysis
- 21.7. Key Players - Intensity Mapping
- 21.8. Country Level Analysis & Forecast
- 21.8.1. GCC Countries Market
- 21.8.1.1. Introduction
- 21.8.1.2. Market Analysis and Forecast by Market Taxonomy
- 21.8.1.2.1. By Product
- 21.8.1.2.2. By Application
- 21.8.1.2.3. By End User
- 21.8.2. Kingdom of Saudi Arabia Market
- 21.8.2.1. Introduction
- 21.8.2.2. Market Analysis and Forecast by Market Taxonomy
- 21.8.2.2.1. By Product
- 21.8.2.2.2. By Application
- 21.8.2.2.3. By End User
- 21.8.3. Türkiye Market
- 21.8.3.1. Introduction
- 21.8.3.2. Market Analysis and Forecast by Market Taxonomy
- 21.8.3.2.1. By Product
- 21.8.3.2.2. By Application
- 21.8.3.2.3. By End User
- 21.8.4. Northern Africa Market
- 21.8.4.1. Introduction
- 21.8.4.2. Market Analysis and Forecast by Market Taxonomy
- 21.8.4.2.1. By Product
- 21.8.4.2.2. By Application
- 21.8.4.2.3. By End User
- 21.8.5. South Africa Market
- 21.8.5.1. Introduction
- 21.8.5.2. Market Analysis and Forecast by Market Taxonomy
- 21.8.5.2.1. By Product
- 21.8.5.2.2. By Application
- 21.8.5.2.3. By End User
- 21.8.6. Israel Market
- 21.8.6.1. Introduction
- 21.8.6.2. Market Analysis and Forecast by Market Taxonomy
- 21.8.6.2.1. By Product
- 21.8.6.2.2. By Application
- 21.8.6.2.3. By End User
- 22. Market Structure Analysis
- 22.1. Market Analysis by Tier of Companies
- 22.2. Market Share Analysis of Top Players
- 22.3. Market Presence Analysis
- 22.3.1. Regional footprint of Players
- 22.3.2. Platform Type foot print by Players
- 22.3.3. Channel Foot Print by Players
- 23. Competition Analysis
- 23.1. Competition Dashboard
- 23.2. Competition Benchmarking
- 23.3. Competition Deep Dive
- 23.3.1. Eli Lilly and Company
- 23.3.1.1. Company Overview
- 23.3.1.2. Product Portfolio
- 23.3.1.3. Sales Footprint
- 23.3.1.4. Key Financials
- 23.3.1.5. SWOT Analysis
- 23.3.1.6. Key Developments
- 23.3.1.7. Strategy Overview
- 23.3.1.7.1. Channel Strategy
- 23.3.1.7.2. Marketing Strategy
- 23.3.1.7.3. Product Strategy
- 23.3.2. Blue Earth Diagnostics
- 23.3.2.1. Company Overview
- 23.3.2.2. Product Portfolio
- 23.3.2.3. Sales Footprint
- 23.3.2.4. Key Financials
- 23.3.2.5. SWOT Analysis
- 23.3.2.6. Key Developments
- 23.3.2.7. Strategy Overview
- 23.3.2.7.1. Channel Strategy
- 23.3.2.7.2. Marketing Strategy
- 23.3.2.7.3. Product Strategy
- 23.3.3. Lantheus
- 23.3.3.1. Company Overview
- 23.3.3.2. Product Portfolio
- 23.3.3.3. Sales Footprint
- 23.3.3.4. Key Financials
- 23.3.3.5. SWOT Analysis
- 23.3.3.6. Key Developments
- 23.3.3.7. Strategy Overview
- 23.3.3.7.1. Channel Strategy
- 23.3.3.7.2. Marketing Strategy
- 23.3.3.7.3. Product Strategy
- 23.3.4. Siemens Healthcare Private Limited
- 23.3.4.1. Company Overview
- 23.3.4.2. Product Portfolio
- 23.3.4.3. Sales Footprint
- 23.3.4.4. Key Financials
- 23.3.4.5. SWOT Analysis
- 23.3.4.6. Key Developments
- 23.3.4.7. Strategy Overview
- 23.3.4.7.1. Channel Strategy
- 23.3.4.7.2. Marketing Strategy
- 23.3.4.7.3. Product Strategy
- 23.3.5. GE Healthcare
- 23.3.5.1. Company Overview
- 23.3.5.2. Product Portfolio
- 23.3.5.3. Sales Footprint
- 23.3.5.4. Key Financials
- 23.3.5.5. SWOT Analysis
- 23.3.5.6. Key Developments
- 23.3.5.7. Strategy Overview
- 23.3.5.7.1. Channel Strategy
- 23.3.5.7.2. Marketing Strategy
- 23.3.5.7.3. Product Strategy
- 23.3.6. Advanced Accelerator Applications (Novartis)
- 23.3.6.1. Company Overview
- 23.3.6.2. Product Portfolio
- 23.3.6.3. Sales Footprint
- 23.3.6.4. Key Financials
- 23.3.6.5. SWOT Analysis
- 23.3.6.6. Key Developments
- 23.3.6.7. Strategy Overview
- 23.3.6.7.1. Channel Strategy
- 23.3.6.7.2. Marketing Strategy
- 23.3.6.7.3. Product Strategy
- 23.3.7. University of Lowa HealthCare
- 23.3.7.1. Company Overview
- 23.3.7.2. Product Portfolio
- 23.3.7.3. Sales Footprint
- 23.3.7.4. Key Financials
- 23.3.7.5. SWOT Analysis
- 23.3.7.6. Key Developments
- 23.3.7.7. Strategy Overview
- 23.3.7.7.1. Channel Strategy
- 23.3.7.7.2. Marketing Strategy
- 23.3.7.7.3. Product Strategy
- 23.3.8. Telix Pharmaceuticals Limited
- 23.3.8.1. Company Overview
- 23.3.8.2. Product Portfolio
- 23.3.8.3. Sales Footprint
- 23.3.8.4. Key Financials
- 23.3.8.5. SWOT Analysis
- 23.3.8.6. Key Developments
- 23.3.8.7. Strategy Overview
- 23.3.8.7.1. Channel Strategy
- 23.3.8.7.2. Marketing Strategy
- 23.3.8.7.3. Product Strategy
- 23.3.9. Jubilant Radiopharma
- 23.3.9.1. Company Overview
- 23.3.9.2. Product Portfolio
- 23.3.9.3. Sales Footprint
- 23.3.9.4. Key Financials
- 23.3.9.5. SWOT Analysis
- 23.3.9.6. Key Developments
- 23.3.9.7. Strategy Overview
- 23.3.9.7.1. Channel Strategy
- 23.3.9.7.2. Marketing Strategy
- 23.3.9.7.3. Product Strategy
- 23.3.10. TRASIS
- 23.3.10.1. Company Overview
- 23.3.10.2. Product Portfolio
- 23.3.10.3. Sales Footprint
- 23.3.10.4. Key Financials
- 23.3.10.5. SWOT Analysis
- 23.3.10.6. Key Developments
- 23.3.10.7. Strategy Overview
- 23.3.10.7.1. Channel Strategy
- 23.3.10.7.2. Marketing Strategy
- 23.3.10.7.3. Product Strategy
- 23.3.11. RadioMedix Inc.
- 23.3.11.1. Company Overview
- 23.3.11.2. Product Portfolio
- 23.3.11.3. Sales Footprint
- 23.3.11.4. Key Financials
- 23.3.11.5. SWOT Analysis
- 23.3.11.6. Key Developments
- 23.3.11.7. Strategy Overview
- 23.3.11.7.1. Channel Strategy
- 23.3.11.7.2. Marketing Strategy
- 23.3.11.7.3. Product Strategy
- 23.3.12. IBA Radiopharma Solutions
- 23.3.12.1. Company Overview
- 23.3.12.2. Product Portfolio
- 23.3.12.3. Sales Footprint
- 23.3.12.4. Key Financials
- 23.3.12.5. SWOT Analysis
- 23.3.12.6. Key Developments
- 23.3.12.7. Strategy Overview
- 23.3.12.7.1. Channel Strategy
- 23.3.12.7.2. Marketing Strategy
- 23.3.12.7.3. Product Strategy
- 23.3.13. Piramal Imaging (Life Molecular Imaging)
- 23.3.13.1. Company Overview
- 23.3.13.2. Product Portfolio
- 23.3.13.3. Sales Footprint
- 23.3.13.4. Key Financials
- 23.3.13.5. SWOT Analysis
- 23.3.13.6. Key Developments
- 23.3.13.7. Strategy Overview
- 23.3.13.7.1. Channel Strategy
- 23.3.13.7.2. Marketing Strategy
- 23.3.13.7.3. Product Strategy
- 23.3.14. Cardinal Health
- 23.3.14.1. Company Overview
- 23.3.14.2. Product Portfolio
- 23.3.14.3. Sales Footprint
- 23.3.14.4. Key Financials
- 23.3.14.5. SWOT Analysis
- 23.3.14.6. Key Developments
- 23.3.14.7. Strategy Overview
- 23.3.14.7.1. Channel Strategy
- 23.3.14.7.2. Marketing Strategy
- 23.3.14.7.3. Product Strategy
- 23.3.15. DuchemBio, Co., Ltd
- 23.3.15.1. Company Overview
- 23.3.15.2. Product Portfolio
- 23.3.15.3. Sales Footprint
- 23.3.15.4. Key Financials
- 23.3.15.5. SWOT Analysis
- 23.3.15.6. Key Developments
- 23.3.15.7. Strategy Overview
- 23.3.15.7.1. Channel Strategy
- 23.3.15.7.2. Marketing Strategy
- 23.3.15.7.3. Product Strategy
- 24. Assumptions and Acronyms Used
- 25. Research Methodology
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
